Cart summary

You have no items in your shopping cart.

DY-131

SKU: orb1222970

Description

DY131, also known as GSK-9089, is a novel selective agonist at estrogen-related receptors ERRβ and ERRγ. DY131 could potentiate the ERRgamma-induced growth inhibition in LNCaP-ERRgamma and DU145-ERRgamma cells in a dose-dependent manner. ERRgamma may perform an antiproliferative or tumor-suppressing function in prostate cancer cells. ERRgamma could be a novel therapeutic target for prostate cancer treatment.

Images & Validation

Key Properties

CAS Number95167-41-2
MW311.38
Purity>98% (HPLC)
FormulaC18H21N3O2
SMILESC(=O)(c1ccc(cc1)O)N/N=C/c1ccc(cc1)N(CC)CC
TargetEphrin Receptor
SolubilityDMSO : 50 mg/mL. 160.58 mM;

Bioactivity

In Vivo
DY131 (5 μg/kg; subcutaneous injection; every second day; for 12 days) treatment increases P450 side-chain cleavage (P450scc), StAR and HMGCoA reductase (HMGCR) while decreases hormone sensitive lipase (HSL) expressions. Animal model: Mature male mice (C57BL/6) (8-10 week-old; ~24.3 g). Dosage: 5 μg/kg. Administration: Subcutaneous injection; every second day; for 12 days. Result: Increased P450scc, StAR and HMGCR while decreased HSL expressions.
In Vitro
DY131 (0.1-30 μM; 5 days) treatment suppresses cell proliferation and reduces BrdUrd-positive cells in both LNCaP-ERRγ and LNCaP cells in a dose-dependent manner, with higher suppression in LNCaP-ERRγ clone. DY131 inhibits Shh induced accumulation of Smo:: EGFP with an IC50 of 0.8 μM. DY131 suppresses SAG (100 nM) induced accumulation of Smo EGFP in the primary cilium and Gli transcription activity with an IC50 of ~2 μM. DY131 dramatically decreases phosphorylated histone H3 (pH3) marked proliferation of CGNPs induced by Shh. A selective ERRγ agonist, DY131, inhibits the growth of the ERα-positive endometrial cancer cells but promoted that of the ERα-negative cancer cells. Cell Proliferation Assay Cell line: LNCaP-ERRγ and LNCaP cells. Concentration: 0.1 μM, 1 μM, 10 μM, 30 μM Incubation time: 5 days. Result: Suppressed cell proliferation and reduced BrdUrd-positive cells in both LNCaP-ERRγ and LNCaP cells in a dose-dependent manner.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

DY131 | DY-131 | DY 131 | GSK-9089

Similar Products

  • DY131 [orb1305897]

    99.66% (May vary between batches)

    95167-41-2

    311.38

    C18H21N3O2

    5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO), 200 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

DY-131 (orb1222970)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

500 mg
5 mg
$ 90.00
10 mg
$ 140.00
25 mg
$ 230.00
50 mg
$ 400.00
100 mg
$ 610.00
200 mg
$ 840.00